Medicus Pharma to Present Phase 1 Teverelix Data Showing Three-Week Hormone Suppression
Medicus Pharma will present Phase 1 Teverelix data from two placebo-controlled studies in 48 premenopausal women at the AACE Annual Meeting April 22–24 in Las Vegas. Single 30–60 mg injections achieved LH/FSH suppression within 24 hours lasting up to three weeks, with stable bone markers and no serious adverse events.
1. Teverelix Phase 1 Data Selected for AACE Annual Meeting
Medicus Pharma confirmed that its abstract “Evaluation of Teverelix, a Long-Acting GnRH Antagonist: Pharmacokinetics, Pharmacodynamics, Bone Turnover and Safety in Two Phase 1 Studies in Healthy Female Volunteers” has been accepted as an e-Poster presentation at the American Association of Clinical Endocrinology Annual Meeting, April 22–24, 2026 in Las Vegas. The acceptance follows submission of detailed findings from two randomized, placebo-controlled Phase 1 studies involving 48 healthy premenopausal women, underscoring the company’s ability to generate decision-grade data for its long-acting GnRH antagonist platform.
2. Robust Hormone Suppression with Preserved Bone Turnover
Across single subcutaneous doses of 30 mg, 45 mg and 60 mg Teverelix or placebo, investigators observed rapid luteinizing hormone and follicle-stimulating hormone suppression within 24 hours. Estradiol levels fell into the clinically relevant 30–50 pg/mL range for multiple participants, a window linked to symptom control without significant bone loss. Hormone suppression persisted up to three weeks at higher dose levels, while bone turnover markers remained stable over the one-month follow-up, indicating no short-term bone safety concerns. The studies reported no drug-related serious adverse events and only mild-to-moderate treatment-emergent events.
3. Strategic Advancement into Women’s Health and Prostate Cancer
Chief Executive Dr. Raza Bokhari emphasized that Phase 1 results support expansion of Teverelix into a women’s health indication such as endometriosis, affecting approximately 10% of reproductive-age women worldwide. Regulatory planning is underway for a Genomics-informed Phase 2 study in symptomatic endometriosis patients in the United Arab Emirates. Concurrently, the immediate receptor antagonism profile of Teverelix—avoiding the initial hormonal surge seen with GnRH agonists—positions it for development in advanced prostate cancer patients with elevated cardiovascular risk, where controlled FSH suppression may reduce adverse outcomes.
4. Partnering-Focused Development Model and Pipeline Updates
Medicus maintains a partnering strategy, advancing assets through Phase 2 proof-of-concept before seeking licensing or co-development agreements. Alongside Teverelix, the company’s SkinJect™ microneedle array platform for basal cell carcinoma has completed enrollment of 90 patients in its Phase 2 SKNJCT-003 trial, with topline decision-grade data expected in Q1 2026. An End-of-Phase 2 meeting with the U.S. Food and Drug Administration is planned for H1 2026, reflecting Medicus’s commitment to assembling robust clinical packages to drive strategic collaborations and commercialization opportunities.